Skip to main content

2015 to 2021 Saw Marked Rise in PCSK9 Inhibitor Utilization

Medically reviewed by Carmen Pope, BPharm. Last updated on March 5, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, March 5, 2024 -- Barriers for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use persist for cholesterol management, according to a research letter published online Feb. 16 in Circulation: Cardiovascular Quality and Outcomes.

Diane E. MacDougall, from the Family Heart Foundation in Fernandina Beach, Florida, and colleagues characterized PCSK9i uptake and durable PCSK9i coverage status using U.S. health care claims data sourced from Symphony Health (July 2015 and December 2021).

The researchers found that 238,704 patients were newly prescribed a PCSK9i from 2015 to 2018, which increased to 470,018 patients from 2019 to 2021. The number of patients with paid prescriptions in the first 90 days rose by 2.7-fold from 85,215 to 234,703 during the two time periods. Yet paid prescription rates for initial PCSK9i coverage (35.70 to 49.93 percent) remained substantially lower than that for other guideline-recommended cardiometabolic therapies (ranging from 68.49 to 84.45 percent).

“Patients still experience substantial challenges getting the PCSK9i that have been prescribed for them by their medical team, despite guidelines recommending their use and extensive evidence documenting their role in low-density lipoprotein cholesterol reduction and the prevention of heart attack or stroke," MacDougall said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

Read this next

Apple Cider Vinegar Beneficial for Overweight, Obese Individuals

WEDNESDAY, March 13, 2024 -- For overweight and obese individuals, apple cider vinegar (ACV) consumption is associated with a significant reduction in anthropometric variables, as...

Dyslipidemia Raising Risk for CVD Among Young American Indians

TUESDAY, March 12, 2024 -- Dyslipidemia is associated with subclinical and clinical cardiovascular disease (CVD) among young American Indians, according to a study published...

Risk Factor Control May Modify Link Between HIV Status and Heart Disease

MONDAY, Jan. 22, 2024 -- Control of dyslipidemia and diabetes, but not hypertension, reduces the association of HIV status with cardiovascular disease (CVD), according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.